Using immune cells from soft tissue sarcoma to create personalized cancer treatments
Leveraging the Lymphocytic Infiltration of Soft Tissue Sarcoma for Autologous Cellular Immunotherapy
This study is testing a new cancer treatment that uses your own immune cells to help fight metastatic soft tissue sarcoma, and it's designed for patients like you who want a personalized approach to their care.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-10889139 on NIH RePORTER |
What this research studies
This research focuses on developing a new type of cancer treatment called autologous cellular immunotherapy, which uses immune cells taken from patients' own tumors. The principal investigator, Dr. Mullinax, aims to expand tumor-infiltrating lymphocytes (TIL) from soft tissue sarcoma to create a personalized therapy that targets the cancer more effectively. The study will assess the safety and feasibility of this treatment in patients with metastatic soft tissue sarcoma, leveraging advanced bioinformatics and clinical trial methodologies. Patients participating in this trial will contribute to the understanding of how their immune cells can be used to fight their cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic soft tissue sarcoma who are seeking innovative treatment options.
Not a fit: Patients with early-stage soft tissue sarcoma or those who do not have sufficient tumor tissue for immune cell extraction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized cancer treatments for patients with soft tissue sarcoma.
How similar studies have performed: Previous research has shown promising results with similar approaches in other types of cancers, indicating potential for success in this novel application.
Where this research is happening
Tampa, United States
- H. Lee Moffitt Cancer Ctr & Res Inst — Tampa, United States (Active)
Researchers
- Principal investigator: Mullinax, John — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Mullinax, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.